| INTRODUC TI ON
Entirely subcutaneous implantable cardioverter defibrillators (S-ICD™; Boston Scientific Corp., Marlborough, MA, USA) provide effective defibrillation and reduce the risk of infection or lead problems. [1] [2] [3] However, as patients with bradycardia pacing indications are excluded from S-ICD therapy because the device lacks the capability for defibrillation in this patient group, they are used less than transvenous implantable cardioverter defibrillators (ICDs). Leadless pacemaker (LP) systems have recently been developed, and their combined use with S-ICD provides a potential solution to the problem with S-ICD use without transvenous leads for patients with an ICD together with pacing indications. 1 The LP system was approved for use in Japan in September 2017.
| C A S E REP ORT
A 72-year-old woman who underwent aortic valve replacement surgery because of aortic valve regurgitation with heart failure in 2010 and aortic valve re-replacement and mitral valve replacement surgery because of prosthetic valve endocarditis (PVE) in 2014 presented to our department. It was determined that she needed lifelong antibiotic therapy because she had repetitive PVE caused by
Staphylococcus agaractiae.
In 2018, she experienced sustained ventricular tachycardia, and her left ventricular ejection fraction was 45%. Considering the history of recurrent infection, S-ICD was preferred over transvenous ICD. Therefore, she received an S-ICD for secondary prophylaxis against sudden cardiac death. The generator automatically selected a secondary shocking vector as the optimal sensing and gain selection
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The subcutaneous implantable cardioverter defibrillator (S-ICD) system was developed for defibrillation therapy that does not affect the heart and vasculature. S-ICD 
| D ISCUSS I ON
The LP is expected to reduce cardiac implantable electronic device infections because this system has no physical connection between the endocardium and subcutaneous pocket. 2 Moreover, the contact surface is small, and the composition of the device's surface was not adequately viable for bacteria. Indeed, there have been no reports of uncontrollable infection with LPs so far. No device has to be explanted despite infection. 4 There have been reports that the problem associated with S-ICD use in bradycardic patients could be solved by combining it with LPs. 
| CON CLUS IONS
We report the first case of successful implantation of an S-ICD and a LP in a Japanese patient with recurrent PVE. There were no associated complications with the device implantation, and there was no interaction between the S-ICD and LP.
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